Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab

Rituximab is a pioneering anti-CD20 monoclonal antibody that became the first-line drug used in immunotherapy of B-cell malignancies over the last twenty years. Rituximab activates the complement system in vitro, but there is an ongoing debate on the exact role of this effector mechanism in therapeu...

Full description

Bibliographic Details
Main Authors:	Anna Felberg, Michał Taszner, Aleksandra Urban, Alan Majeranowski, Kinga Jaskuła, Aleksandra Jurkiewicz, Grzegorz Stasiłojć, Anna M. Blom, Jan M. Zaucha, Marcin Okrój
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Immunology
Subjects:	obinutuzumab (GA101) non-Hodgkin’s lymphoma complement system chronic lymphocytic leukemia rituximab
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.584509/full

Similar Items

In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies
by: Aleksandra Urban, et al.
Published: (2022-03-01)

The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
by: Alicja Kuźniewska, et al.
Published: (2023-12-01)

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
by: Luan C, et al.
Published: (2019-08-01)

Editorial: Complement and Immunotherapeutics
by: Marcin Okrój, et al.
Published: (2021-02-01)

Gain of function mutant of complement factor B K323E mimics pathogenic C3NeF autoantibodies in convertase assays
by: Aleksandra Urban, et al.
Published: (2018-01-01)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
by: Al-Sawaf O, et al.
Published: (2017-01-01)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
by: Jennifer R. Blase, et al.
Published: (2022-04-01)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
by: Laurie H. Sehn, et al.
Published: (2020-06-01)

An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab
by: Tali Shafat, et al.
Published: (2024-02-01)

Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
by: Martina Bogeljić Patekar, et al.
Published: (2018-01-01)

Anti-CD20 monoclonal antibodies: reviewing a revolution
by: J. M. L. Casan, et al.
Published: (2018-12-01)

A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature
by: Noa Bigman-Peer, et al.
Published: (2022-08-01)

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
by: Shlomo Elias, et al.
Published: (2018-06-01)

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
by: Casado LF, et al.
Published: (2016-09-01)

Use of rituximab in NHL malt type pregnant in I° trimester for two times
by: Sica Antonello, et al.
Published: (2019-11-01)

Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab
by: Daniela Viecceli, et al.

The Role of Rituximab in Lymphomas
by: Bertrand Coiffier
Published: (2002-01-01)

Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care
by: Mary Ann Anderson, et al.
Published: (2024-02-01)

Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine
by: Jan-Paul Bohn, et al.
Published: (2022-02-01)

Disseminated Enteroviral Infection Associated with Obinutuzumab
by: Claire Dendle, et al.
Published: (2015-09-01)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
by: Jamie B. Oughton, et al.
Published: (2017-07-01)

Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia
by: Yao Zhang, et al.
Published: (2024-01-01)

Successful Rapid Desensitization of Two Teenagers with Rituximab Hypersensitivity
by: Murat Cansever, et al.
Published: (2019-05-01)

Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
by: Igor Aurer, et al.
Published: (2024-01-01)

Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy
by: Seki M, et al.
Published: (2022-12-01)

New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
by: Biswanath Basu, et al.
Published: (2022-02-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Combined chemoimmunotherapy of patients with mature B-cell non-Hodgkin lymphomas age group until 18 years: results of multicenter study NHL 2004 m with rituximab and modified B-NHL BFM 90 protocol applications
by: E. V. Samochatova, et al.
Published: (2022-11-01)

Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma
by: Sandra Lara, et al.
Published: (2022-06-01)

Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells
by: Eleonora Vecchio, et al.
Published: (2024-02-01)

Linfoma hepático primario: Evolución favorable con quimioterapia combinada con rituximab Primary hepatic lymphoma: favorable outcome with chemotherapy plus rituximab
by: I. Serrano-Navarro, et al.
Published: (2008-11-01)

Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review
by: Deirdre Kelly, MBBCH, et al.
Published: (2016-09-01)

Rituximab-induced interstitial pneumonitis in patient with non-Hodgkin lymphoma: a clinical case
by: Nikolai A. Ognerubov, et al.
Published: (2022-08-01)

Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis
by: Sabine Tacke, et al.
Published: (2022-03-01)

Isolation of SARS-CoV-2 in Viral Cell Culture in Immunocompromised Patients With Persistently Positive RT-PCR Results
by: Abby Sung, et al.
Published: (2022-02-01)

Substitutions at position 263 within the von Willebrand factor type A domain determine the functionality of complement C2 protein
by: Alicja Kuźniewska, et al.
Published: (2022-12-01)

Gain-of-Function Mutations R249C and S250C in Complement C2 Protein Increase C3 Deposition in the Presence of C-Reactive Protein
by: Aleksandra Urban, et al.
Published: (2021-11-01)

Fate of 177Lu-CHX-A”-DTPA-Rituximab: In vitro Evaluation in Raji Cell Line
by: Saloni Arun Samant, et al.
Published: (2023-01-01)

Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates
by: Petros Ioannou, et al.
Published: (2023-03-01)